BRITISH HEART JOURNAL Editorial Antihypertensive drugs and plasma lipids
There has been increasing concern expressed about the possible adverse effects upon lipid metabolism of the two major classes of agent used in treating blood pressurethiazide diuretics and ,B blockers. Although these effects of diuretics have been recognised for over 15 years,' only recently have they begun to have a major impact upon prescribing policy. There are two reasons for this. Firstly, newer classes of agent that are free of these effects were intensively marketed in the 1980s. The competitive advantage of agents such as angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and a adrenoceptor blockers in terms oftheir effects upon plasma lipids has been pressed home and has led to a decline in the prescription of diuretics and ,B blockers in several countries. Secondly, and perhaps more legitimately, it has been suggested that adverse metabolic disturbances account for the apparently disappointing impact of antihypertensive drug therapy upon the incidence ofischaemic heart disease. Thus in the large major multicentre trials of antihypertensive treatment, myocardial infarction was reduced only in the Hypertension, Detection and Follow-Up Programme (HDFP).2 A meta-analysis of the large trials showed a nonsignificant reduction in coronary morbidity and mortality that was only about a third of the excess risk borne by the patients with hypertension.3 This contrasted with apparent complete reversal of the stroke risk attributable to hypertension. A later meta-analysis subtly altered the conclusion, largely because several smaller trials in moderate as well as mild hypertension were included.4 This metaanalysis calculated a 14% fall in the incidence of coronary heart disease compared with an expected fall of 20-25%. Unfortunately, the wide 95% confidence limits (4-22%) for this pooled analysis are compatible with virtually no effect on the one hand or complete reversal of risk on the other.
It is perhaps not entirely surprising that there are residual uncertainties about the impact of antihypertensive therapy on coronary artery disease. Other risk factors play a greater role in coronary artery disease whereas blood pressure is the predominant risk factor for stroke. Though epidemiological associations predict a 35-40% reduction in the incidence of stroke the same data predict a reduction in coronary artery disease of only 20-25% as a result of blood pressure reduction.4
It is possible therefore that there is no shortfall in the impact ofantihypertensive treatment on myocardial infarction and that the uncertainties arise because the existing studies lack statistical power. I think this is unlikely, however. The difficulty with meta-analysis is that it pools studies independently of the rigour of their design. The 14% reduction in the incidence of coronary heart disease owes much to the significant fall of 19-8% in the HDFP group,2 compared with a fall of only 5-1% in the Medical Research Council (MRC) trial of treatment of mild hypertension. The control group in the HDFP study were patients who had been referred back to their usual medical care whereas the MRC trial had a blinded placebo control group. The fall in incidence in the other 12 trials pooled in a meta-analysis was perhaps closer to the results of the MRC trial than the HDFP study.
It seems likely therefore that there is a shortfall in the impact of antihypertensive therapy upon ischaemic heart disease. How Quantitatively, drug-induced changes in cholesterol are insufficient to contribute substantially to the apparently disappointing impact of antihypertensive treatment on myocardial infarction. In the MRC trial bendrofluazide treatment increased cholesterol by 0 1 mmol/l in men and 0 14 mmol/l in women." In this trial differences in plasma cholesterol of this magnitude was associated with a 3-4% increase in the risk of a coronary event, while the shortfall in impact upon infarction was, as we have seen, 15-20%. In a separate analysis of the pooled cholesterol data from the MRC and HDFP trial Collins et al estimated that diuretic therapy increased total cholesterol overall by about 1% and that such an increase would have been associated with an increase in coronary heart disease of only 2% over the duration of the trials if extrapolation from epidemiological associations to clinical trials was valid. 4 There is further direct evidence that diuretic or # blocker therapy does not have a pro-atheromatous effect. Thus most strokesin patients with mild hypertension are atherothrombotic rather than haemorrhagic. The 
